NCT07146802Recruiting
Personalized Metacognitive Training for Psychosis: A Randomized Controlled Trial
Towards a Personalized Medicine Approach to Psychological Treatment for Psychosis
Source: ClinicalTrials.gov · Last updated 20 Aug 2026
Brief summary (registry, in English)
This study aims to compare the efficacy of classical Metacognitive Training (MCT) and personalized Metacognitive Training (P-MCT) for individuals with psychosis. MCT is a psychoeducational program derived from cognitive-behavioral therapy (CBT) that targets cognitive biases associated with psychotic symptoms. The goal is to assess which intervention is more effective to improve the overall functioning of individuals with psychosis. The study will use machine learning to personalize the treatment approach and evaluate its impact on clinical symptoms, cognitive functions, and quality of life.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 51 (estimated)
- First submitted
- 1 Aug 2025
- Start date
- 3 Apr 2026
- Primary completion date
- 1 Apr 2027
- Lead sponsor
- University Hospital, Strasbourg, France
- Diseases
- Schizophrenia
- NCT number
- NCT07146802
What you commit to
- Study type: Interventional
- Planned participants: 51
- From 3 Apr 2026 to the primary completion date, 1 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Having received MCT in the previous year.
- Patient considered by his psychiatrist to be at serious risk of harm to self or others (e.g. previous aggressive or suicidal behaviors)
Other illness
- Neurological disorder, or severe medical condition other than psychosis
Other
- A score above 5 in the "Hostility" and the "Suspiciousness" items of the PANSS Positive subscale (to preserve group dynamics).
- Patient in an exclusion period defined by another research protocol
- Patient involved in another Investigational Medicinal Product trial
- Patient under guardianship (i.e. French "tutelle")
- Patients deprived of freedom because of a judicial measure.
Who the study is looking for
- Adults, 18 - 65 years of age.
- Patient affiliated to health insurance
- Inpatients and outpatients with DSM-5 diagnosis of schizophrenia spectrum disorder.
- Presence of positive symptoms at inclusion (PANSS delusions, suspiciousness or grandiosity ≥3).
- Stable condition with no expected changes in medication or symptoms during the last 3 months (information from clinical services, note that stable condition includes lack of suicidality).
- Patient providing informed consent.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Service de psychiatrie Coordinator of this site? Confirm its status | Strasbourg | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.